- Home
- BBUC vs ARQT Comparison
BBUC vs ARQT Comparison
Compare BBUC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBUC
- ARQT
- Stock Information
- Founded
- BBUC 2022
- ARQT 2016
- Country
- BBUC United States
- ARQT United States
- Employees
- BBUC N/A
- ARQT N/A
- Industry
- BBUC
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- BBUC
- ARQT Health Care
- Exchange
- BBUC Nasdaq
- ARQT Nasdaq
- Market Cap
- BBUC 2.4B
- ARQT 2.1B
- IPO Year
- BBUC N/A
- ARQT 2020
- Fundamental
- Price
- BBUC $33.72
- ARQT $20.74
- Analyst Decision
- BBUC
- ARQT Strong Buy
- Analyst Count
- BBUC 0
- ARQT 7
- Target Price
- BBUC N/A
- ARQT $19.00
- AVG Volume (30 Days)
- BBUC 157.2K
- ARQT 1.9M
- Earning Date
- BBUC 11-06-2025
- ARQT 10-28-2025
- Dividend Yield
- BBUC 0.75%
- ARQT N/A
- EPS Growth
- BBUC N/A
- ARQT N/A
- EPS
- BBUC N/A
- ARQT N/A
- Revenue
- BBUC $8,240,000,000.00
- ARQT $263,464,999.00
- Revenue This Year
- BBUC N/A
- ARQT $72.46
- Revenue Next Year
- BBUC N/A
- ARQT $31.69
- P/E Ratio
- BBUC N/A
- ARQT N/A
- Revenue Growth
- BBUC 6.96
- ARQT 99.50
- 52 Week Low
- BBUC $21.52
- ARQT $8.03
- 52 Week High
- BBUC $37.01
- ARQT $21.30
- Technical
- Relative Strength Index (RSI)
- BBUC 47.17
- ARQT 68.31
- Support Level
- BBUC $32.97
- ARQT $16.68
- Resistance Level
- BBUC $34.42
- ARQT $21.30
- Average True Range (ATR)
- BBUC 1.23
- ARQT 1.00
- MACD
- BBUC -0.22
- ARQT 0.25
- Stochastic Oscillator
- BBUC 45.61
- ARQT 89.84
About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.